• Mashup Score: 0
    Amplifying RNA vaccines - a way forward for CAR-T-cell therapy? - 2 year(s) ago

    Early clinical findings with the anti-claudin-6 CAR-T-cell product BNT211, with or without amplifying vaccine, in patients with solid tumours

    Source: Daily Reporter
    Categories: Hem/Onc News and Journals, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of myESMO
      myESMO

      #ESMOImmuno21: Amplifying #RNAvaccines the way forward in #CARTcell therapy? Early clinical findings w/ anti-claudin-6 CAR-T-cell product BNT211, w/ or not amplifying vaccine, in pts w/ refractory solid tumours promising but more data needed https://t.co/ZIQK7oPrFM #immunotherapy https://t.co/HoSLTE7EuO

  • Mashup Score: 1
    ESMO Immuno-Oncology Congress 2021: Programme - 2 year(s) ago

    The ESMO Immuno-Oncology 2021 programme is now online!

    Source: www.esmo.org
    Categories: Hem/Oncs, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of StephenVLiu
      StephenVLiu

      #ESMOImmuno21 Looking forward to discussing the role of immunotherapy in thoracic cancers (#MPM, NSCLC, #SCLC, thymic cancers) with co-panelists Drs. @MdCurioni @peters_solange @DrRoyHerbstYale tomorrow: Friday, Dec 10 (16:30 CEST, 10:30 EST). Join us! https://t.co/5h6V4r44ja

  • Mashup Score: 6
    ESMO Immuno-Oncology Congress 2021 - 2 year(s) ago

    A virtual congress, taking place on 8-11 December 2021

    Source: www.esmo.org
    Categories: Hem/Onc News and Journals, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of myESMO
      myESMO

      #ESMOImmuno21 Guidelines session: Management of toxicities from #immunotherapy ⏰ Dec 9 2021 9:00AM CET ➡️ https://t.co/SMzUIe7WRX Register here 👉 https://t.co/nFzV8ettqT #immunooncology #cancerresearch @HaanenJohn https://t.co/p9HJ1uYfvf

  • Mashup Score: 5
    Developing immunotherapies for mesothelioma  - Daily Reporter - 2 year(s) ago

    Along with treatments with immune checkpoint inhibitors and cellular therapies, other immunotherapies are currently under investigation

    Source: Daily Reporter
    Categories: Hem/Onc News and Journals, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of myESMO
      myESMO

      #ESMOImmuno21: Along with treatments with immune checkpoint inhibitors and cellular therapies, other #immunotherapies are currently under investigation. 👉 https://t.co/5vIQhad4gL Educational session, 10/12, 16:30, Room A #mesothelioma #lcsm #CARTcells @MdCurioni https://t.co/j3b0Ii8Jtx

  • Mashup Score: 5
    Is tumour mutational burden predictive enough? - 2 year(s) ago

    Data suggest that assessing the quality as well as the quantity of tumour mutations may enhance prediction of immunotherapy outcomes

    Source: Daily Reporter
    Categories: Hem/Onc News and Journals, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of myESMO
      myESMO

      #ESMOImmuno21: Tumour mutational burden as a number – is it predictive enough? Assessing quality as well as quantity of tumour #mutations may enhance prediction of outcomes in pts treated w/ immune checkpoint inhibitors https://t.co/322sFJo5AE @ChristianRolfo #TMB #immunotherapy https://t.co/JCSTRbLoRV

  • Mashup Score: 0
    How to use biomarkers to improve outcomes with immunotherapy - 2 year(s) ago

    According to Samra Turajlic, broadening tumour sampling and expanding the characterisation methodologies used are promising strategies

    Source: Daily Reporter
    Categories: Hem/Onc News and Journals, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of myESMO
      myESMO

      #ESMOImmuno21: The complexity of identifying & clinically validating #immunotherapy #biomarkers can be addressed by broadening tumour sampling & expanding characterisation methodologies used 👉 https://t.co/6D9D8NdCJf @SamraTurajlic #immunooncology #immunotherapy #cancerresearch https://t.co/wodsf3EA2e

  • Mashup Score: 1
    New immunotherapies for solid tumours - 2 year(s) ago

    From cell-based therapies to soluble T-cell engagers and T-cell co-stimulation, early findings show novel promising strategies

    Source: Daily Reporter
    Categories: Hem/Onc News and Journals, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of myESMO
      myESMO

      #ESMOImmuno21: New #immunotherapies explored to improve treatment of solid tumours. From cell-based therapies to soluble #Tcell engagers & T-cell co-stimulation, early findings show novel promising strategies, but more data needed https://t.co/A2iockFJ6Y @DoniaMarco #CARTcell https://t.co/jswu27FxTl

  • Mashup Score: 2
    Immunotherapy: from scepticism to the heart of cancer care - 2 year(s) ago

    Prof. Wolf H. Fridman comments on the prognostic and predictive role of the tumour microenvironment

    Source: Daily Reporter
    Categories: Hem/Onc News and Journals, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of myESMO
      myESMO

      #ESMOImmuno21 - Award 2021 lecture 'The crucial players of the immune microenvironment' by Wolf-Hervé Fridman, winner of the ESMO #Immuno-Oncology 2021 Award 📌 Today (8 Dec) at 12:45 CET Daily Reporter article 👉 https://t.co/J3HuECteTn Platform: https://t.co/kCstf8ALXY https://t.co/rBjPj6WmaG

Load More